Article: Hana Biosciences a Bit Early - Analyst Blog

Hana Biosciences a Bit Early - Analyst Blog

Hana Biosciences Inc. ( HNAB ) has a relatively diversified portfolio but all candidates are in either early stage or middle stage of development. We don't see huge upside potential for Hana shares in the next 6 to 12 months.

The company's cash position is also a matter of concern. As of June 30, Hana had aggregate cash and cash equivalents and available-for-sale securities of $9.3 million. When the company advances its candidates into late stage clinical trials, research and development costs will soar in the next few years. Hana may need to tap the capital market as early as in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!